SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-003295 to Exscientia plc (EXAI) (CIK 0001865408)

Exscientia plc (EXAI) (CIK 0001865408)
Date: March 26, 2024 · CIK: 0001865408 · Accession: 0000000000-24-003295

AI Filing Summary & Sentiment

File numbers found in text: 333-278132

Date
March 26, 2024
Author
Not clearly detected
Form
UPLOAD
Company
Exscientia plc (EXAI) (CIK 0001865408)

Letter

United States securities and exchange commission logo March 26, 2024 Dan Ireland Vice President, Legal Exscientia plc The Schrödinger Building Oxford Science Park Oxford OX4 4GE United Kingdom Re:Exscientia plc Registration Statement on Form F-3 Filed March 21, 2024 File No. 333-278132 Dear Dan Ireland: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Boles

Show Raw Text
United States securities and exchange commission logo
March 26, 2024
Dan Ireland
Vice President, Legal
Exscientia plc
The Schrödinger Building
Oxford Science Park
Oxford OX4 4GE
United Kingdom
Re:Exscientia plc
Registration Statement on Form F-3
Filed March 21, 2024
File No. 333-278132
Dear Dan Ireland:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       David Boles